• Sibanye-Stillwater entered a research collaboration with South African Nuclear Energy Corporation (Necsa) to develop radioactive palladium isotope Palladium-103 derived from rhodium for cancer treatment.
• Initial phase calls for Necsa to test rhodium against radionuclide production standards.
• Necsa will conduct chemical work to produce high-purity Pd-103 for potential use in targeted radionuclide therapy.
• Second phase targets additional nuclear medicine applications using rhodium plus other platinum group metals from Sibanye-Stillwater.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sibanye Stillwater Limited published the original content used to generate this news brief on April 17, 2026, and is solely responsible for the information contained therein.